Patrick R. Bergevin

437 total citations
12 papers, 335 citations indexed

About

Patrick R. Bergevin is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Patrick R. Bergevin has authored 12 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Patrick R. Bergevin's work include Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (2 papers) and Chemotherapy-induced cardiotoxicity and mitigation (2 papers). Patrick R. Bergevin is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (2 papers) and Chemotherapy-induced cardiotoxicity and mitigation (2 papers). Patrick R. Bergevin collaborates with scholars based in United States, Uganda and France. Patrick R. Bergevin's co-authors include Johannes Blom, Fred R. Dick, Ivan P. Law, P. Schein, Peter H. Wiernik, Vincent T. DeVita, M J O'Connell, S M Hubbard, I T Magrath and J. L. Ziegler and has published in prestigious journals such as Cancer, Medical Clinics of North America and Southern Medical Journal.

In The Last Decade

Patrick R. Bergevin

11 papers receiving 281 citations

Peers

Patrick R. Bergevin
Salvador Bruno United States
Susan Weaver United States
Walter B. Lundberg United States
A. Jobke Germany
B. Isaacs United States
Helen Yang United States
Alan C. Homans United States
Salvador Bruno United States
Patrick R. Bergevin
Citations per year, relative to Patrick R. Bergevin Patrick R. Bergevin (= 1×) peers Salvador Bruno

Countries citing papers authored by Patrick R. Bergevin

Since Specialization
Citations

This map shows the geographic impact of Patrick R. Bergevin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick R. Bergevin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick R. Bergevin more than expected).

Fields of papers citing papers by Patrick R. Bergevin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick R. Bergevin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick R. Bergevin. The network helps show where Patrick R. Bergevin may publish in the future.

Co-authorship network of co-authors of Patrick R. Bergevin

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick R. Bergevin. A scholar is included among the top collaborators of Patrick R. Bergevin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick R. Bergevin. Patrick R. Bergevin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Bergevin, Patrick R., et al.. (2005). Le seigneur des anneaux. Enfances & Psy. n o 27(2). 86–95. 2 indexed citations
2.
Bergevin, Patrick R., et al.. (1996). Recognizing delirium in terminal patients. American Journal of Hospice and Palliative Medicine®. 13(2). 28–29. 6 indexed citations
3.
Bergevin, Patrick R., et al.. (1995). Recognizing depression. American Journal of Hospice and Palliative Medicine®. 12(5). 22–23. 6 indexed citations
4.
Bergevin, Patrick R., et al.. (1995). Discussing DNR issues. American Journal of Hospice and Palliative Medicine®. 12(3). 10–11. 1 indexed citations
5.
Nissen, Nis I., Thomas F. Pajak, Louis A. Leone, et al.. (1980). Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B. Cancer. 45(2). 232–235. 56 indexed citations
6.
Tong, Charles C. L., et al.. (1978). Inhibition of Growth of Mouse Ehrlich Ascites by Normal Tissue Extracts. Chemotherapy. 24(1). 34–38. 3 indexed citations
7.
Bergevin, Patrick R.. (1976). The Increasing Problem of Malignancy in the Elderly: New Concepts in Diagnosis and Management. Medical Clinics of North America. 60(6). 1241–1251. 4 indexed citations
8.
Bergevin, Patrick R., et al.. (1976). Pernicious Anemia Terminating in Acute Myeloblastic Leukemia. Southern Medical Journal. 69(1). 110–112.
9.
Law, Ivan P., Fred R. Dick, Johannes Blom, & Patrick R. Bergevin. (1975). Involvement of the central nervous system in non-hodgkin's lymphoma. Cancer. 36(1). 225–231. 107 indexed citations
10.
Tormey, D. C., Patrick R. Bergevin, Johannes Blom, & W. Jeffrey Petty. (1974). Preliminary trials with a combination of adriamycin (NSC-123127) and bleomycin (NSC-125066) in adult malignancies.. PubMed. 57(4). 413–8. 8 indexed citations
11.
Schein, P., M J O'Connell, Johannes Blom, et al.. (1974). Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer. 34(4). 993–1000. 138 indexed citations
12.
Bergevin, Patrick R., D C Tormey, & Jannet Blom. (1972). Guide to the use of cancer chemotherapeutic agents.. PubMed. 9(2). 185–273. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026